Sponsors / ORKA
ORKA

Oruka Therapeutics, Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
5Trials in this database
9Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque PsoriasisNCT07090330ORKAPhase 2Active not recruiting2026-03-25Actual
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque PsoriasisNCT07290569ORKAPhase 2Active not recruiting2027-06Estimated
An Open-Label Extension Study of ORKA-001 in Participants With Plaque PsoriasisNCT07449702ORKAPhase 2Recruiting2030-05Estimated
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque PsoriasisNCT07474792ORKAPhase 2Recruiting2027-10Estimated
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis SuppurativaNCT07783542ORKAPhase 2Recruiting2028-10Estimated

Latest recorded trial changes

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

NCT07449702 · Oruka Therapeutics, Inc.

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)

+ After

Measure: Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)

Planned enrollment increased by 160 participants

− Before

80 participants (planned)

+ After

240 participants (planned)

Primary completion date changed

− Before

Nov 2028

+ After

May 2030

Check registry source